Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
More News
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Immunic advances MS drug toward key Phase 3 data, expects results by year-end...
Yahoo! Finance: News
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire NEW YORK, Aug. 11, 2026 Leadership Team Expanded with Key Executive Appointments, Including Chief Executive...
PR Newswire
Immunic Appoints Elena Ridloff to Board of Directors
Immunic Appoints Elena Ridloff to Board of Directors Immunic Appoints Elena Ridloff to Board of Directors PR Newswire NEW YORK, Aug. 10, 2026 Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in...
PR Newswire
Immunic to Participate in Investor Conferences in July
Immunic to Participate in Investor Conferences in July Immunic to Participate in Investor Conferences in July PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company pioneering the development of novel oral therapies...
PR Newswire
Immunic to Participate in Investor, Industry and Scientific Conferences in June
Immunic to Participate in Investor, Industry and Scientific Conferences in June Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire NEW YORK, June 10, 2026 NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company...
PR Newswire
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026...
PR Newswire
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials...
Yahoo! Finance: News
Immunic Names Erik Lundgren Chief Executive Officer
(RTTNews) - Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1...
Nasdaq News: Markets
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PR Newswire NEW YORK, May 27, 2026 Proven Leader with Deep Multiple Sclerosis Expertise; Played Key...
PR Newswire

Advertisement|Remove ads.